Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

Summary

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $438.4 billion in 2019.The US was the fastest growing country, with a CAGR of 3.4% over the 2015-19 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $409.4 billion in 2019. This was followed by Canada and Mexico, with a value of $23.8 and $5.3 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $417.2 billion in 2024, followed by Canada and Mexico with expected values of $26.8 and $5.5 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to Buy

- What was the size of the NAFTA pharmaceuticals market by value in 2019?
- What will be the size of the NAFTA pharmaceuticals market in 2024?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?

1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Pharmaceuticals
2.1. Industry Outlook
3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Pharmaceuticals in Mexico
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 Pharmaceuticals in The United States
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Company Profiles
6.1. Johnson & Johnson
6.2. Pfizer Inc.
6.3. Apotex Pharmachem Inc
6.4. Merck & Co., Inc.
6.5. Bayer AG
6.6. Novartis AG
6.7. AstraZeneca AB
7 Appendix
7.1. Methodology
7.2. About MarketLine

List Of Tables

Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-24
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-19
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2019-24
Table 4: Canada pharmaceuticals market value: $ billion, 2015-19
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2019
Table 6: Canada pharmaceuticals market share: % share, by value, 2019
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Table 8: Canada size of population (million), 2015-19
Table 9: Canada gdp (constant 2005 prices, $ billion), 2015-19
Table 10: Canada gdp (current prices, $ billion), 2015-19
Table 11: Canada inflation, 2015-19
Table 12: Canada consumer price index (absolute), 2015-19
Table 13: Canada exchange rate, 2015-19
Table 14: Mexico pharmaceuticals market value: $ billion, 2015-19
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2019
Table 16: Mexico pharmaceuticals market share: % share, by value, 2019
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2019-24
Table 18: Mexico size of population (million), 2015-19
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2015-19
Table 20: Mexico gdp (current prices, $ billion), 2015-19
Table 21: Mexico inflation, 2015-19
Table 22: Mexico consumer price index (absolute), 2015-19
Table 23: Mexico exchange rate, 2015-19
Table 24: United States pharmaceuticals market value: $ billion, 2015-19
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2019
Table 26: United States pharmaceuticals market share: % share, by value, 2019
Table 27: United States pharmaceuticals market value forecast: $ billion, 2019-24
Table 28: United States size of population (million), 2015-19
Table 29: United States gdp (constant 2005 prices, $ billion), 2015-19
Table 30: United States gdp (current prices, $ billion), 2015-19
Table 31: United States inflation, 2015-19
Table 32: United States consumer price index (absolute), 2015-19
Table 33: United States exchange rate, 2015-19
Table 34: Johnson & Johnson: key facts
Table 35: Johnson & Johnson: Annual Financial Ratios
Table 36: Johnson & Johnson: Key Employees
Table 37: Johnson & Johnson: Key Employees Continued
Table 38: Pfizer Inc.: key facts
Table 39: Pfizer Inc.: Annual Financial Ratios
Table 40: Pfizer Inc.: Key Employees
Table 41: Pfizer Inc.: Key Employees Continued
Table 42: Apotex Pharmachem Inc: key facts
Table 43: Apotex Pharmachem Inc: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Bayer AG: key facts
Table 49: Bayer AG: Annual Financial Ratios
Table 50: Bayer AG: Key Employees
Table 51: Novartis AG: key facts
Table 52: Novartis AG: Annual Financial Ratios
Table 53: Novartis AG: Annual Financial Ratios (Continued)
Table 54: Novartis AG: Key Employees
Table 55: Novartis AG: Key Employees Continued
Table 56: AstraZeneca AB: key facts
Table 57: AstraZeneca AB: Key Employees

List Of Figures

Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-24
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2015-19
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2019-24
Figure 4: Canada pharmaceuticals market value: $ billion, 2015-19
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 6: Canada pharmaceuticals market share: % share, by value, 2019
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2019-24
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2019
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2019
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2019
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2019
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2019
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2019
Figure 14: Mexico pharmaceuticals market value: $ billion, 2015-19
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2019
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2019-24
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2019
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2019
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2019
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2019
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2019
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2019
Figure 24: United States pharmaceuticals market value: $ billion, 2015-19
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 26: United States pharmaceuticals market share: % share, by value, 2019
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2019-24
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2019
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2019
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2019
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2019
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2019
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2019

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available